[1]Matsuda T, Kambe N, Ueki Y, et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation[J]. Ann Rheum Dis, 2020, 79: 1492-1499. [2]Dugan J, Griffiths E, Snow P, et al. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice[J]. J Immunol, 2015, 194: 349-357. [3]Salem M, Seidelin JB, Rogler G, et al. Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond[J]. Cell Mol Life Sci, 2013, 70: 3391-3404. [4]Zhang Y, Lian M, Zhao X, et al. RICK regulates the odontogenic differentiation of dental pulp stem cells through activation of TNF-α via the ERK and not through NF-κB signaling pathway[J]. Cell Biol Int, 2021, 45: 569-579. [5]Zheng Y, Shang F, An L, et al. NOD2-RIP2 contributes to the inflammatory responses of mice in vivo to Streptococcus pneumoniae[J]. Neurosci Lett, 2018, 671: 43-49. [6]Lauro ML, D'Ambrosio EA, Bahnson BJ, et al. Molecular recognition of muramyl dipeptide occurs in the leucine-rich repeat domain of Nod2[J]. ACS Infect Dis, 2017, 3: 264-270. [7]Mensa-Vilaro A, Cham WT, Tang SP, et al. Brief report: first identification of intrafamilial recurrence of Blau syndrome due to gonosomal NOD2 mosaicism[J]. Arthritis Rheumatol, 2016, 68: 1039-1044. [8]Okazaki F, Wakiguchi H, Korenaga Y, et al. A novel mutation in early-onset sarcoidosis/Blau syndrome: an association with Propionibacterium acnes[J]. Pediatr Rheumatol Online J, 2021, 19: 18. doi: 10.1186/s12969-021-00505-5. [9]Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, et al. Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfec-tious uveitis[J]. Mediators Inflamm, 2013: 286857. doi: 10.1155/2013/286857. [10]Lu L, Shen M, Jiang D, et al. Blau syndrome with good reponses to tocilizumab: a case report and focused literature review[J]. Semin Arthritis Rheum, 2018, 47: 727-731. [11]Hrdinka M, Schlicher L, Dai B, et al. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling[J]. Embo J, 2018, 37: doi: 10.15252/embj.201899372. |